Eubel Brady & Suttman Asset Management Inc. Has $24.66 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Eubel Brady & Suttman Asset Management Inc. raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.4% during the 4th quarter, HoldingsChannel reports. The firm owned 233,456 shares of the medical equipment provider’s stock after purchasing an additional 3,128 shares during the quarter. Zimmer Biomet comprises 3.3% of Eubel Brady & Suttman Asset Management Inc.’s holdings, making the stock its 8th biggest position. Eubel Brady & Suttman Asset Management Inc.’s holdings in Zimmer Biomet were worth $24,660,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Roman Butler Fullerton & Co. bought a new stake in Zimmer Biomet during the 4th quarter valued at approximately $473,000. Geode Capital Management LLC boosted its position in shares of Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after acquiring an additional 125,852 shares during the period. M&T Bank Corp grew its stake in shares of Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after acquiring an additional 8,709 shares during the last quarter. KLCM Advisors Inc. bought a new position in Zimmer Biomet during the fourth quarter worth $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new position in Zimmer Biomet during the 4th quarter valued at $654,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $104.89 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The company has a 50 day moving average of $105.86 and a 200-day moving average of $107.47. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market cap of $20.88 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the business posted $2.20 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Analyst Ratings Changes

Several analysts have issued reports on the stock. JMP Securities restated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Wells Fargo & Company lifted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Raymond James decreased their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.